D'Amico Ferdinando, Magro Fernando, Caron Benedicte, Dignass Axel, Jairath Vipul, Hart Ailsa, Kotze Paulo Gustavo, Paridaens Kristine, Awadhi Sameer Al, Kobayashi Taku, Siegmund Britta, Peyrin-Biroulet Laurent, Danese Silvio
Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, 20132 Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.
J Clin Med. 2023 Feb 1;12(3):1142. doi: 10.3390/jcm12031142.
The i Support Therapy-Access to Rapid Treatment (iSTART) was an initiative to improve patient-centered management in mild-to-moderate ulcerative colitis (UC). Our aim was to update the iSTART recommendations in order to include fecal calprotectin (FC) in the monitoring of patients with UC and improve their management. Twelve physicians from nine countries worldwide attended a virtual international consensus meeting on 4 May 2022. Data from three systematic reviews were analyzed, and a new systematic review investigating all studies reporting measurement of FC at home was conducted. Based on literature evidence, statements were formulated, discussed, and approved by voting. Statements were considered approved if at least 75% of participants agreed with a proposed statement. Fourteen statements were approved. Based on this consensus, FC measurement should be routinely performed for monitoring patients with mild-to-moderate UC to identify disease relapses early and initiate an appropriate treatment. Further studies are needed to assess whether self-monitoring of FC is associated with better disease control and improved patients' quality of life.
“我支持治疗——快速治疗途径”（iSTART）是一项旨在改善轻至中度溃疡性结肠炎（UC）以患者为中心管理的倡议。我们的目标是更新iSTART建议，以便将粪便钙卫蛋白（FC）纳入UC患者的监测并改善其管理。来自全球九个国家的12名医生参加了2022年5月4日的虚拟国际共识会议。分析了三项系统评价的数据，并开展了一项新的系统评价，调查所有报告在家中测量FC的研究。基于文献证据制定陈述，进行讨论并通过投票批准。如果至少75%的参与者同意一项提议陈述，则该陈述被视为批准。14项陈述获得批准。基于这一共识，应常规进行FC测量以监测轻至中度UC患者，以便早期识别疾病复发并启动适当治疗。需要进一步研究以评估FC自我监测是否与更好的疾病控制和改善患者生活质量相关。
